Stryker Corporation (SYK)
NYSE: SYK · Real-Time Price · USD
336.74
+6.49 (1.97%)
At close: Jul 27, 2026, 4:00 PM EDT
337.23
+0.49 (0.15%)
After-hours: Jul 27, 2026, 7:51 PM EDT
Stryker Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 25,270 | 25,116 | 22,595 | 20,498 | 18,449 | 17,108 |
Revenue Growth | 8.84% | 11.16% | 10.23% | 11.11% | 7.84% | 19.21% |
Gross Profit Gross Profit Growth | 16,131 | 16,065 | 14,440 | 13,058 | 11,578 | 10,968 |
Operating Income Operating Income Growth | 4,988 | 4,889 | 3,689 | 3,888 | 2,841 | 2,584 |
Net Income Net Income Growth | 3,337 | 3,246 | 2,993 | 3,165 | 2,358 | 1,994 |
Earnings Per Share EPS Growth | 8.64 | 8.40 | 7.76 | 8.25 | 6.17 | 5.21 |
EPS Growth | 16.76% | 8.25% | -5.94% | 33.71% | 18.43% | 24.05% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Instruments (Pre FY-2026 Reporting) Instruments (Pre FY-2026 Reporting) Growth | - | 3,183 | 2,834 | 2,534 | 2,279 | 2,111 |
Endoscopy Endoscopy Growth | 3,808 | 3,807 | 3,389 | 3,068 | 2,725 | 2,418 |
Medical Medical Growth | 4,161 | 4,204 | 3,852 | 3,459 | 3,031 | 2,607 |
Neurovascular Neurovascular Growth | 2,079 | 1,968 | 1,307 | 1,226 | 1,200 | 1,188 |
Neuro Cranial Neuro Cranial Growth | - | 2,485 | 2,136 | 1,876 | 1,376 | 1,214 |
Knees Knees Growth | 2,687 | 2,656 | 2,447 | 2,273 | 1,997 | 1,848 |
Hips Hips Growth | 1,882 | 1,865 | 1,704 | 1,544 | 1,413 | 1,342 |
Trauma and Extremities Trauma and Extremities Growth | 4,038 | 3,948 | 3,507 | 3,147 | 2,807 | 2,664 |
Spinal Implants Spinal Implants Growth | 21 | 185 | 707 | 713 | 1,146 | 1,167 |
Other Orthopaedics Other Orthopaedics Growth | - | 815 | 712 | 658 | 475 | 549 |
Revenue (Total) Revenue (Total) Growth | 25,270 | 25,116 | 22,595 | 20,498 | 18,449 | 17,108 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,965 | 4,100 | 4,493 | 3,053 | 1,928 | 3,019 |
Total Debt Total Debt Growth | 14,723 | 15,859 | 13,597 | 12,995 | 13,048 | 12,479 |
Net Cash (Debt) Net Cash Growth | -11,758 | -11,759 | -9,104 | -9,942 | -11,120 | -9,460 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -30.42 | -30.42 | -23.61 | -25.91 | -29.09 | -24.74 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 5,375 | 5,044 | 4,242 | 3,711 | 2,624 | 3,263 |
Capital Expenditures CapEx Growth | -804 | -761 | -755 | -575 | -588 | -525 |
Free Cash Flow Free Cash Flow Growth | 4,571 | 4,283 | 3,487 | 3,136 | 2,036 | 2,738 |
Free Cash Flow Growth | 27.79% | 22.83% | 11.19% | 54.03% | -25.64% | -1.86% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 63.83% | 63.96% | 63.91% | 63.70% | 62.76% | 64.11% |
Operating Margin | 19.74% | 19.47% | 16.33% | 18.97% | 15.40% | 15.10% |
Pretax Margin | 18.20% | 17.97% | 15.45% | 17.92% | 14.54% | 13.33% |
Profit Margin | 13.21% | 12.92% | 13.25% | 15.44% | 12.78% | 11.66% |
FCF Margin | 18.09% | 17.05% | 15.43% | 15.30% | 11.04% | 16.00% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 3.520 | 3.400 | 3.240 | 3.050 | 2.835 | 2.585 |
Dividend Per Share Growth | 4.82% | 4.94% | 6.23% | 7.58% | 9.67% | 9.77% |
Dividend Yield | 1.05% | 0.96% | 0.89% | 1.00% | 1.14% | 0.94% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 38.98 | 41.84 | 46.40 | 36.30 | 39.63 | 51.33 |
Forward PE | 21.45 | 24.23 | 27.41 | 26.45 | 25.33 | 26.92 |
P/FCF Ratio | 28.24 | 31.21 | 39.38 | 36.30 | 45.48 | 36.87 |
PS Ratio | 5.11 | 5.32 | 6.08 | 5.55 | 5.02 | 5.90 |